ONC.TO

Oncolytics Biotech Inc. [ONC.TO] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ONC.TO Stock Summary

Top 10 Correlated ETFs

ONC.TO

Top 10 Correlated Stocks

ONC.TO

In the News

ONC.TO Financial details

Company Rating
-
Market Cap
116.15M
Income
-27.42M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
29
Optionable
No
Shortable
Yes
Earnings
03 May 2024
P/E
-3.62
Forward P/E
-
PEG
8.46
P/S
-
P/B
3.99
P/C
-
P/FCF
-4.31
Quick Ratio
4.05
Current Ratio
4.53
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.41
EPS next Y
-
EPS next Q
-
EPS this Y
-4.65%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-61.71%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-69%
ROE
-124%
ROC
-0.92%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.2-4.49
52W High
-80.5%
52W Low
-22%
RSI
48
Rel Volume
0.34
Avg Volume
83.38K
Volume
28.58K
Perf Week
-7.14%
Perf Month
-12.36%
Perf Quarter
-48%
Perf Half Y
-54.12%
-
-
-
-
Beta
1.46
-
-
Volatility
0.02%, 0.06%
Prev Close
-4.88%
Price
0.78
Change
0%

Something similar

Top by Market Cap
VTSAX
3V64.DE
M&M.NS
LLY.DE
DHR-PB
Top Correlated ETFs
ARKG
KORU
GNOM
CNCR
EWY
Top Correlated Stocks
ONCY
RXRX
5658.T
7885.T
VOR
Similar Market Cap
LS.TO
NTIC
SANCO.NS
8372.HK
XYLG

Company Profile

Healthcare Biotechnology
  • Volume Average 83.38K
  • Market Capitalization 116.15M
  • Employee 29
  • CEO Dr. Matthew C. Coffey M.B.A., Ph.D.
  • Headquarters Calgary,AB,CA
  • IPO Date 2000-06-01
  • Website https://www.oncolyticsbiotech.com

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.